OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Kin on the Withdrawal of Belantamab Mafodotin in R/R Multiple Myeloma

March 27th 2023

Andrew Kin, MD, discusses the withdrawal of the United States marketing authorization of belantamab mafodotin for the treatment of patients with relapsed/refractory multiple myeloma who have received at least 4 prior therapies, including an anti-CD38 monoclonal antibody, a proteasome inhibitor, and an immunomodulatory agent.

Dr Dorigo on the Clinical Benefit with Maveropepimut-S in Recurrent Ovarian Cancer

March 27th 2023

Oliver Dorigo, MD, PhD, discusses the clinical efficacy of maveropepimut-S in patients with recurrent ovarian cancer.

Dr Polan on Perioperative Outcomes With Supracervical or Total Hysterectomy Plus Colorectal Resection

March 27th 2023

Rosa M. Polan, MD, discusses key data from a comparison of perioperative outcomes with supracervical and total hysterectomy performed with concurrent colorectal resection in women.

Dr Coleman on Response Rates With Mirvetuximab Soravtansine in Ovarian Cancer

March 27th 2023

Robert L. Coleman, MD, FACOG, FACS, discusses an analysis of the phase 3 SORAYA trial evaluating response rates in patients with platinum-resistant ovarian cancer who received mirvetuximab soravtansine at different points in their disease course.

Dr Matulonis on Second-line Maintenance Therapy With Niraparib in Ovarian Cancer

March 27th 2023

Ursula A. Matulonis, MD, discusses final overall survival results from the phase 3 NOVA trial in patients with ovarian cancer.

Dr. Cortes on Defining Fitness in Patients With Hematologic Malignancies

March 24th 2023

Jorge E. Cortes, MD, discusses the importance of defining fitness in patients with hematologic malignancies prior to treatment selection.

Dr Randall on the Presentation and Symptoms of Mesenchymal Chondrosarcoma

March 24th 2023

R. Lor Randall, MD, FACS, discusses the potential symptoms and presentation of mesenchymal chondrosarcoma, as well as highlighted recent case studies that he consulted on for patients with mesenchymal chondrosarcoma.

Dr Carey on Response-Guided Therapy in HER2+ Breast Cancer

March 24th 2023

Lisa A. Carey MD, ScM, FASCO, discusses the varying approaches to response-guided therapy in HER2-positive breast cancer.

Dr Vidal on the Need for Improved Clinical Trial Representation in Breast Cancer

March 24th 2023

Gregory Vidal, MD, PhD, explains why clinical trials need to be more representative of the whole breast cancer population, in order to account for differences in biology and social determinants.

Dr Hill on Efficacy of Dostarlimab in dMMR Locally Advanced Rectal Cancer

March 24th 2023

Joshua Hill, MD, MS, discussed the early efficacy of dostarlimab in mismatch repair–deficient locally advanced rectal cancer.

Dr Khalil on the Use of Nivolumab/Ipilimumab Combination in NSCLC

March 24th 2023

Maya Khalil, MD, discusses key clinical trial updates on the use of nivolumab and ipilimumab with or without chemotherapy in non–small cell lung cancer.

Dr Zonder on the Expansion of Targeted Therapies in R/R Multiple Myeloma

March 24th 2023

Jeffery Zonder, MD, discusses the need for expanding the armamentarium of targeted therapies for patients with relapsed/refractory multiple myeloma.

Dr Zonder on CAR T-cell Therapy Vs Bispecific Antibodies in Relapsed/Refractory Myeloma

March 23rd 2023

Jeffery Zonder, MD, discusses the process of choosing between CAR T-cell therapy and bispecific antibody approaches for the treatment of patients with relapsed/refractory multiple myeloma.

Dr Brahmer on First-line Tremelimumab/Durvalumab Plus Chemotherapy in NSCLC

March 23rd 2023

Julie Renee Brahmer, MD, discusses the use of tremelimumab plus durvalumab and platinum-based chemotherapy for the first-line treatment of patients with non–small cell lung cancer, and how decisions can be made between this regimen and nivolumab plus ipilimumab and chemotherapy.

Dr Mitzman on the Emergence of Immunotherapy in Early-Stage NSCLC

March 23rd 2023

Brian Mitzman, MD, FACS, FCCP, discusses the emergence of immunotherapy as a treatment option for patients with early-stage non–small cell lung cancer.

Dr Christensen on Azacitidine Plus Venetoclax in AML

March 23rd 2023

Bradley W. Christensen, MD, discusses findings from the phase 3 VIALE-A trial in patients with acute myeloid leukemia.

Dr. Chiang on Advancements in the Treatment and Characterization of SCLC

March 23rd 2023

Anne Chiang, MD, PhD, discusses recent advancements in the biological understanding and treatment of small cell lung cancer.

Dr. Roque on the Importance of Biomarker Testing in Advanced Endometrial Cancer

March 23rd 2023

Dario R. Roque, MD, discusses how biomarker testing can lead to more accurate and effective treatment selection in advanced endometrial cancer.

Dr Callander on Early CAR T-cell Therapy Referrals in Multiple Myeloma

March 23rd 2023

Natalie S. Callander, MD, discusses the potential benefits of referring patients with multiple myeloma to CAR T-cell therapy earlier in their disease course.

Dr Henick on Biomarker Detection in Lung Cancer

March 22nd 2023

Brian Henick, MD, discusses the different ways to identify biomarkers of immunotherapy response in patients with lung cancer and how refining these approaches may improve individualized treatment approaches in the future.